undamentalytics Newsletter
Sign in

Dare Bioscience, Inc. income statement

In fiscal 2025, Dare Bioscience, Inc. reported revenue of $1.0m, up 10429.4% on the year before, operating income of −$13.6m (a -1315.5% margin) and net income of −$13.4m, or −$1.20 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2012Dec 20122013Dec 20132014Dec 20142016Dec 20162021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue10010103011
Cost of revenue———————00—
Gross profit———————01—
Research and development16101203130221463
Selling, general and administrative———————99—
General and administrative669081112———
Operating income———−1−39−31−31−23−14−11
Interest expense1110——————
Income before tax———−1−39−31−30−4−14—
Income tax————00000—
Net income−22−17−23−1−39−31−30−4−13−11
Diluted EPS−$4366.80−$3006.00−$192.00−$9.72−$0.63−$0.37−$4.15−$0.48−$1.20−$0.78
Diluted shares (average)————5m7m7m8m11m14m
EBITDA———−0−39−31−31−23−12−9

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: DARE vs RNACABSI vs DAREDARE vs LGVNDARE vs OVID

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Dare Bioscience, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Dare Bioscience, Inc.